Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Kubota, K., Hida, T., Ishikura, S., Mizusawa, J., Nishio, M., Kawahara, M., Yokoyama, A., Imamura, F., Takeda, K., Negoro, S., & others The Lancet Oncology, 15(1):106–113, 2014.
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study [link]Paper  bibtex   
@article{kubota_etoposide_2014,
	title = {Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy ({JCOG0202}): a randomised phase 3 study},
	volume = {15},
	shorttitle = {Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy ({JCOG0202})},
	url = {http://www.sciencedirect.com/science/article/pii/S1470204513705114},
	number = {1},
	urldate = {2017-05-22},
	journal = {The Lancet Oncology},
	author = {Kubota, Kaoru and Hida, Toyoaki and Ishikura, Satoshi and Mizusawa, Junki and Nishio, Makoto and Kawahara, Masaaki and Yokoyama, Akira and Imamura, Fumio and Takeda, Koji and Negoro, Shunichi and {others}},
	year = {2014},
	pages = {106--113},
}

Downloads: 0